Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Sesame Care vs Eve

Two GLP-1 desks, one scoreboard. We put Sesame Care and Eve head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 4 · Grade B+

Sesame Care

Visit Sesame Care Full brief →
vs
No. 334 · Grade C

Eve

Visit Eve Full brief →

The verdict

Sesame Care takes this head-to-head.

Sesame Care scores 87 to 59 on our six-factor Brief Score — An established national telehealth marketplace with the widest real brand-name GLP-1 access on the board — Wegovy (pen and pill), Zepbound, Ozempic and Mounjaro — plus provider-by-provider price transparency.

That doesn't make Eve a bad call — it's best for readers who want women's-health glp-1 with compounded or brand-name access. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
84
48
Supply Reliability
92
71
Transparency
94
32
Access Breadth
84
62
Clinical Oversight
80
79
Track Record
92
73
Sesame CareBrief Score 87 · 59Eve

Price, coverage & the tracker

Sesame CareEve
Brief Score87/100 (B+)59/100 (C)
SemaglutideFrom $149/mo (brand Wegovy pill)From $195/mo (compounded)
TirzepatideBrand Zepbound (price varies)From $195/mo (compounded)
CoverageNationwide marketplaceCoverage not published
Brand-name accessYesYes
Oral / sublingualYesYes
On the trackerStableprice stableNewnew to the tracker, no prior reading

Sesame Care: Marketplace pricing is set per provider rather than one desk rate; the brand-name Wegovy pill line held its ~$149 entry this cycle.

Eve: New to the tracker on 1 August 2026. The published line reads From $195/mo (compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.